Clinical Research Directory

Inclusion Criteria: * ability to understand and sing written consent * ability to use visual analogue (VAS) and Borg dyspnea scale * presence of lung disease (asthma, chronic obstructive pulmonary disease, interstitial pulmonary disease, tumour affecting lungs, Coronavirus Disease 2019 (COVID19), drug induced dyspnea, lung infection) * dyspnea at least 50 points in VAS and at least 5 point in Borg dyspnea scale * women of childbearing age consent ot avoid sexual intercourse during the study participation Exclusion Criteria: * hypersensitivity to furosemide, levodropropizine or any additives in studied drugs * mucociliary disorder (kartegener syndrome, ciliary dyskinesis) * severe liver disease - cirrhosis Child Pugh B or C * renal failure, creatinine clearance less than 35 ml/min * unstable patient requiring frequent treatment changes * patients with continual intravenous medication requiring modification of their therapy more often than ever 4 hours * unability to participate in all study procedures * pregnancy, breast feeding * participation in other clinical trial with administration of study drug in last 28 days or 5 half times of studied drug (the longer period is taken into account) before screening